Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 29 - June 3, 2026 in Chicago, Illinois.

"This year's ASCO Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date, further underscoring the critical role that multimodal data and AI-driven insights play in advancing precision medicine across oncology," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "The breadth of our findings demonstrates the tangible impact of these tools in transforming complex real-world data into actionable evidence, helping more patients benefit from the next generation of innovative therapies."

Research highlights include:

Saturday, May 30, 2026

9:00am - 12:00pm CT

Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success

Poster Board: 536; Abstract Number: 1618

AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.

Poster Board: 193; Abstract Number: 4210

1:30 pm – 4:30 pm CT

ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy

Poster Board: 199; Abstract Number: 3062

First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF-mutated differentiated thyroid cancer (DTC): Insights from real-world data.

Poster Board: 509; Abstract Number: 6052

Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors

Poster Board: 219; Abstract Number: 3082

Sunday, May 31, 2026

9:00am - 12:00pm CT

Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early-stage NSCLC biomarker testing

Poster Board: 518; Abstract Number: 8044

Monday, June 1, 2026

9:00 am - 12:00 pm CT

Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome

Poster Board: 363; Abstract Number: 6570

1:30 pm - 4:30 pm CT

GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies

Poster Board: 130b; Abstract Number: TPS649

Explore the full scope of Tempus-authored research and discover how the company is advancing precision medicine at the 2026 ASCO Annual Meeting here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526086558/en/

Tempus

Hanah Heintzelman

Hanah.heintzelman@tempus.com

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting